Mode
Text Size
Log in / Sign up
N/A Completed N=134 Treatment

A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.

Source: ClinicalTrials.gov NCT02080871 ↗
Enrolled (actual)
134
Serious AEs
22.4%
Results posted
Jul 2018
Primary outcomePrimary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001

Summary

Evaluation of the Gore(R) VIABAHN BX for the treatment of arterial occlusive disease in the common and/or external iliac arteries.

Outcome Measures

OutcomeResultp-value
PRIMARY
Composite of Major Adverse Events (MAEs)
2.3 <0.001 sig
SECONDARY
Acute Procedural Success
130 —
SECONDARY
30-Day Clinical Success
108 —
SECONDARY
Percentage of Participants With Primary Patency
94.4 —
SECONDARY
Percentage of Participants With Primary Assisted Patency
98.4 —
SECONDARY
Percentage of Participants With Secondary Patency
99.2 —
SECONDARY
Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)
91.4 —
SECONDARY
Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)
97.7 —
SECONDARY
Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)
90.6 —
SECONDARY
Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)
96.1 —
SECONDARY
Number of Participants With Change in Rutherford Category
82; 7; 0 —
SECONDARY
Change in Ankle Brachial Index (ABI)
0.17 —
SECONDARY
Number of Participants With Change in Functional Status - EQ5D - Mobility
43; 43; 4 —
SECONDARY
Number of Participants With Change in Functional Status - EQ5D - Self Care
4; 84; 2 —
SECONDARY
Number of Participants With Change in Functional Status - EQ5D - Usual Activities
44; 42; 4 —
SECONDARY
Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort
39; 44; 7 —
SECONDARY
Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression
27; 58; 5 —
SECONDARY
Number of Participants With Change in Functional Status - EQ5D - Own Health State
21; 56; 12 —
SECONDARY
Number of Participants With Improvement in Functional Status at 30 Days - Walking Improvement Questionnaire (WIQ)
106 —
SECONDARY
Number of Participants With Improvement in Functional Status 9 Months - Walking Improvement Questionnaire (WIQ)
102 —

Eligibility Criteria

Inclusion Criteria

  • Patient is at least 18 years old;
  • Patient is male, infertile female, or female of childbearing potential practicing an acceptable method of preventing pregnancy;
  • Patient or legal representative is willing to give written informed consent;
  • Patient is capable of complying with protocol requirements, including all follow-up visits;
  • Patient has symptomatic claudication or rest pain without tissue loss (Rutherford Categories 2-4).
  • Patient has de novo or restenotic target lesion(s) in the common and/or external iliac artery;
  • Patient has one or more regions of stenosis ≥ 50% in the target vessel, based on visual estimate;
  • Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm;
  • Patient has adequate ipsilateral blood flow including at least one sufficient ( 2.5mg/dL) and not on hemodialysis;
  • Patient has a known hypercoagulability that cannot be corrected;
  • Patient has evidence of a blood borne infection;
  • Patient has had vascular access/catheterization in the lower extremity within 30 days of study enrollment;
  • Patient has had a previous or planned coronary intervention within 30 days prior to enrollment in this study or required at time of study procedure;
  • Patient has had a previous or planned bypass surgery in the target leg, or a bypass that occurs at the time of the index procedure;
  • Patient is currently participating in this or another investigative clinical study.
  • Patient has a stent or stent graft located within or immediately adjacent (≤5mm) to study lesion(s);
  • Patient has evidence of angiographically visible thrombus within or adjacent to the target lesion(s);
  • Patient has aneurysmal dilation proximal or distal to the target lesion(s) that would interfere with the placement of the device;
  • Patient has a target lesion requiring atherectomy or any ablative device to facilitate stent delivery;
  • Patient has a target lesion situated in such a way that an implanted device will prevent blood flow or perfusion to the internal iliac artery if patent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02080871). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search